IM19 CAR-T

BIOLOGICAL4 trials

Sponsors

Beijing Immunochina Medical Science & Technology Co., Ltd.

Conditions

Hematological MalignanciesLeukemia

Phase 1

Safety and Efficacy Evaluation of IM19 CAR-T Cells

Beijing Immunochina Medical Science & Technology Co., Ltd.Leukemia

Start: 2016-08-30End: 2018-10-01Target: 60Updated: 2018-05-01

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

CompletedNCT03173417

Beijing Immunochina Medical Science & Technology Co., Ltd.Leukemia

Start: 2017-05-23End: 2019-05-01Updated: 2019-05-20

Safety and Efficacy Evaluation of IM19 Cells

Beijing Immunochina Medical Science & Technology Co., Ltd.Hematological Malignancies

Start: 2017-08-21End: 2020-12-01Target: 20Updated: 2017-11-17

Unknown Phase

Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation

Beijing Immunochina Medical Science & Technology Co., Ltd.Leukemia

Start: 2019-01-01End: 2021-12-01Target: 20Updated: 2020-12-17

Related Papers

CD72 as a complementary B-lineage marker for longitudinal measurable residual disease surveillance after CD19 CAR-T therapy in R/R B-ALL.

2026-08-03

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Blood2022-11-151 citations

Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy

Blood2021-11-053 citations

Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy

Leukemia & lymphoma/Leukemia and lymphoma2021-10-2116 citations

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.

2021-08-0736 citations

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood2020-11-044 citations

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Blood2020-11-043 citations

Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

Blood2020-11-042 citations

Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features

Blood Advances2020-05-26206 citations

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood2019-11-134 citations

Efficacy and Safety of CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphocytic Leukemia (B-cell ALL) in a Large Cohort Including Patients with Extramedullary Disease(EMD), High Leukemia Burden, BCR-ABL (+) Mutation,TP53 Mutation, and Post-Transplant Relapse

Blood2018-11-297 citations

Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.

Journal of Clinical Oncology2018-05-2015 citations